Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Ann Surg Oncol. 2011 Nov;18(12):3453-61. doi: 10.1245/s10434-011-1751-y. Epub 2011 May 4.
The purpose of this study was to evaluate the impact of tumor morcellation on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma (LGESS).
Outcomes were retrospectively compared between patients with apparently early LGESS who did not (group A, n=27) or did (group B, n=23) undergo tumor morcellation.
There were no between-group differences in age, menopausal status, parity, body mass index, and preoperative presumptive diagnosis, nor were there between-group differences in tumor stage, tumor size, myometrial invasion, lymphovascular space invasion, frequency of ovarian preservation, adjuvant therapy, or follow-up time. More patients in group A underwent lymph node dissection (51.9 vs. 21.7%; P=0.029). Only 1 patient in each group had distant recurrence. There were 2 patients (7.4%) in group A and 7 (31.4%) in group B who had abdominopelvic recurrence. The risk of abdominopelvic recurrence was significantly higher in group B than in group A (odds ratio [OR], 5.47; 95% confidence interval [95% CI], 1.04-29.70; P=0.035). The 5-year disease-free survival (DFS) rates were 84% for group A and 55% for group B (P=0.028) and the 5-year abdominopelvic DFS rates were 89 and 58% (P=0.023), respectively. Multivariate analysis showed that tumor morcellation were significantly associated with poorer DFS (OR, 4.03; 95% CI, 1.06-15.30; P=0.040) and abdominopelvic DFS (OR, 5.06; 95% CI, 1.02-25.04; P=0.047).
Inadvertent tumor morcellation during surgery has an adverse impact on the outcomes of patients with early LGESS.
本研究旨在评估肿瘤分碎对明显早期低度子宫内膜间质肉瘤(LGESS)患者结局的影响。
回顾性比较了未行(A 组,n=27)或行(B 组,n=23)肿瘤分碎的明显早期 LGESS 患者的结局。
A 组和 B 组在年龄、绝经状态、产次、体重指数和术前推测诊断方面无组间差异,在肿瘤分期、肿瘤大小、子宫肌层浸润、淋巴血管空间浸润、卵巢保留频率、辅助治疗或随访时间方面也无组间差异。A 组更多的患者行淋巴结清扫(51.9% vs. 21.7%;P=0.029)。两组各有 1 例远处复发。A 组有 2 例(7.4%)和 B 组有 7 例(31.4%)患者出现腹盆腔复发。B 组腹盆腔复发的风险明显高于 A 组(比值比[OR],5.47;95%置信区间[95%CI],1.04-29.70;P=0.035)。A 组的 5 年无病生存率(DFS)为 84%,B 组为 55%(P=0.028),A 组和 B 组的 5 年腹盆腔 DFS 率分别为 89%和 58%(P=0.023)。多变量分析显示肿瘤分碎与较差的 DFS(OR,4.03;95%CI,1.06-15.30;P=0.040)和腹盆腔 DFS(OR,5.06;95%CI,1.02-25.04;P=0.047)显著相关。
手术中意外的肿瘤分碎对早期 LGESS 患者的结局有不良影响。